1.A.7 ATP-gated P2X Receptor Cation Channel (P2X Receptor) Family

Members of the P2X Receptor family respond to ATP, a functional neurotransmitter released by exocytosis from many types of neurons. They have been placed into seven groups (P2X1 - P2X7) based on their pharmacological properties. These channels, which function at neuron-neuron and neuron-smooth muscle junctions, may play roles in the control of blood pressure and pain sensation. Their structural-fuctional relationships have been examined (Mager et al. 2004), and they are expressed throughout the body, mediating a multitude of functions, including muscle contraction, neuronal excitability and bone formation (Vial et al. 2004). They may function in lymphocyte and platelet physiology. They are found only in eukaryotes. Their ATP binding sites are extracellular and involve residues near ile-67. ATP binding causes the channel to go from the closed to the open state (Kracun et al., 2010). The intracellular amino terminus plays a dominant role in desensitization of P2X receptor ion channels (Allsopp and Evans, 2011). Activation and regulation of purinergic P2X receptor channels has been reviewed by Caddou et al. (2011). The gating mechanism has been proposed (Du et al., 2012). The ion access pathway to the transmembrane pore in P2X receptor channels has been estimated (Kawate et al., 2011). P2X receptor channels show threefold symmetry in ionic charge selectivity and unitary conductance (Browne et al., 2011). The binding of ATP to trimeric P2X receptors (P2XR) causes an enlargement of the receptor extracellular vestibule, leading to opening of the cation-selective transmembrane pore, and specific roles of vestibule amino acid residues in receptor activation have been evaluated (Rokic et al. 2013).

The seven different P2X receptor types differ in their sensitivities to ATP and various ATP analogues as well as in their inactivation kinetics. ATP binding initially causes opening of the non-selective cation channel, allowing Ca2+ entry. Prolonged exposure of slowly inactivating forms to ATP leads to dilation of the pore, making it permeable to larger molecules (up to 1000 Da). Then it functions as a cytolytic pore that is permeable to organic cations such as ethidium and N-methyl-D-glucamine. Formation of this cytolytic pore is regulated by the C-terminal hydrophilic domain in at least one of these receptors (P2X7; Smart et al., 2003). The ion-conducting pathway is formed by three TMS 2 (TMS2) alpha-helices, each being provided by the three subunits of the trimer. P2X receptors are trimeric ATP-activated ion channels permeable to Na+, K+ and Ca+2. The seven P2X receptor subtypes are implicated in physiological processes that include modulation of synaptic transmission, contraction of smooth muscle, secretion of chemical transmitters and regulation of immune responses.

The zebrafish chalice-shaped, trimeric P2X(4) receptor (TC#1.A.7.1.4) is knit together by subunit-subunit contacts implicated in ion channel gating and receptor assembly. Extracellular domains, rich in beta-strands, have large acidic patches that may attract cations, through fenestrations, to vestibules near the ion channel. In the transmembrane pore, the 'gate' is defined by an approximately 8 Å slab of protein. There are three non-canonical, intersubunit ATP-binding sites. ATP binding may promote subunit rearrangement as well as ion channel opening (Kawate et al., 2009).

The P2X1 receptor is the dominant P2X type in smooth muscle neurons. P2X2/P2X3 heterooligomers mediate sensory signals in many other sensory neurons. P2X4 and P2X6 receptors are highly expressed in the central nervous system and probably form heterooligomers. P2X7 is expressed in cells of the immune system and of hematopoetic origin. These channels have a homo- or heterotrimeric architecture (Aschrafi et al., 2004). The carboxy termini influence the regulation of P2X1 receptors (Wen and Evans 2011). N,S-acetal juglone derivatives are inhibitors of the P2X7 receptor-promoted  inflammatory response (Pacheco et al. 2023). Neurosteroids are positive and negative allosteric modulators of ligand-gated ion channels such as the P2X receptor (Sivcev et al. 2023). Subtype-specific ligand-binding and activation gating in homomeric and heteromeric P2X receptors have been described (Brünings et al. 2024).  A subtype-specific pattern of ligand potency and efficacy on human P2X2, P2X3, and P2X2/3 receptors with distinct relations between binding and gaiting was observed. Given the high in vivo concentrations of Mg2+, the complex formed by Mg2+ and ATP emerges as an adequate ligand for P2X receptors (Brünings et al. 2024).

The proteins of the P2X Receptor family are quite similar in sequence, but they possess 380-1000 amino acyl residues per subunit with variability in length localized primarily to the C-terminal domains. They possess two transmembrane spanners, one about 30-50 residues from their N-termini, the other near residues 320-340. The extracellular receptor domains between these two spanners (typically of about 270 residues) are well conserved with several conserved glycyl residues and 10 conserved cysteyl residues. The hydrophilic C-termini vary in length. Like epithelial Na+ channel (ENaC) proteins (TC #1.A.6), they possess (a) N- and C-termini localized intracellularly, (b) two putative transmembrane spanners, (c) a large extracellular loop domain, and (d) many conserved extracellular cysteyl residues. P2X receptor channels are probably hetero- or homomultimers of several subunits and transport small monovalent cations (Me+ and Me++). Some transport Ca2+, and after prolonged exposure to ATP, various metabolites as noted above.

The three-dimensional structure of a P2X receptor is known (Burnstock and Kennedy, 2011). When ATP binds, the pore opens within milliseconds, allowing the cations to flow. P2X receptors are expressed in both central and peripheral neurons where they are involved in neuromuscular and synaptic neurotransmission and neuromodulation. They are also expressed in most types of nonneuronal cells and mediate a wide range of actions, such as contraction of smooth muscle, secretion and immunomodulation. Changes in the expression of P2X receptors have been characterized in many pathological conditions of the cardiovascular, gastrointestinal, respiratory, and urinogenital systems and in the brain and special senses. The therapeutic potential of P2X receptor agonists and antagonists is currently being investigated in a range of disorders, including chronic neuropathic and inflammatory pain, depression, cystic fibrosis, dry eye, irritable bowel syndrome, interstitial cystitis, dysfunctional urinary bladder, and cancer.

Hattori and Gouaux (2012) reported the crystal structure of the zebrafish P2X(4) receptor in complex with ATP and a new structure of the apo receptor. The agonist-bound structure reveals an ATP-binding motif and an open ion channel. ATP binding induces cleft closure of the nucleotide-binding pocket, flexing of the lower body β-sheet and a radial expansion of the extracellular vestibule. The structural widening of the extracellular vestibule is directly coupled to the opening of the ion channel pore by way of an iris-like expansion of the transmembrane helices. In mammals, lithocholic acid inhibits P2X2 and potentiates P2X4 receptor channel gating (Sivcev et al. 2020).

Phosphoinositides modulate the functions of most P2X receptor channels in neurons and glia. A dual polybasic motif has been shown to determine phosphoinositide binding and regulation in members of the P2X channel family (Bernier et al., 2012). Modeling has provided insight into the ligand-binding properties of P2X receptors (Dal Ben et al. 2015). Three distinct roles for P2X7 during adult neurogenesis have been demonstrated, and these depend on the extracellular ATP concentrations:  (i) P2X7 receptors can form transmembrane pores leading to cell death,
(ii) P2X7 receptors can regulate rates of proliferation, likely via calcium signalling and
(iii) P2X7 can function as scavenger receptors in the absence of ATP, allowing neural progenitor cells (NPCs) to phagocytose apoptotic NPCs during neurogenesis (Leeson et al. 2018).

Cys loop, glutamate, and P2X receptors are ligand-gated ion channels (LGICs) with 5, 4, and 3 protomers, respectively. Agonists and competitive antagonists apparently induce opposite motions of the binding pocket (Du et al., 2012b). Agonists, usually small, induce closure of the binding pocket, leading to opening of the channel pore, whereas antagonists, usually large, induce opening of the binding pocket, thereby stabilizing the closed pore. Both P2XRs and 5-HT3Rs, are modulated by pharmacologically relevant concentrations of ethanol, with inhibition or stimulation of P2XR subtypes and stimulation of 5-HT3Rs, respectively (Davies et al. 2006).

The strong expression of ATP-gated P2X3 receptors by a subpopulation of sensory neurons indicates the important role of these membrane proteins in nociceptive signaling in health and disease, especially when the latter is accompanied by chronic pain syndromes. These receptors exist mainly as trimeric homomers, and, in part, as heteromers (assembly of two P2X3 subunits with one P2X2). Recent investigations have suggested distinct molecular determinants responsible for agonist binding and channel opening for transmembrane flux of sodium, calcium and potassium ions. Trimeric P2X3 receptors are rapidly activated by ATP and can be strongly desensitized in the continuous presence of the agonist. Endogenous substances, widely thought to be involved in triggering pain, especially in pathological conditions, can potently modulate the expression and function of P2X3 receptors, with differential changes in response amplitude, desensitization and recovery. Strong facilitation of P2X3 receptor function is induced by enodogenous substances like the neuropeptide calcitonin gene-related peptide and the neurotrophins nerve growth factor and brain-derived neurotrophic factor. These substances possess distinct mechanisms of action on P2X3 receptors, generally attributable to discrete phosphorylation of N- or C-terminal P2X3 domains (Fabbretti and Nistri, 2012).

Two structural classes of pore-opening mechanisms have been established: bending of pore-lining helices in the case of tetrameric cation channels, and tilting of such helices in mechanosensitive channels. Expansion of the gate region in the external pore in P2X receptors is accompanied by a narrowing of the inner pore, indicating that pore-forming helices straighten on ATP binding to open the channel (Li et al., 2010). This pore-opening mechanism has implications for the role of subunit interfaces in the gating mechanism and points to a role of the internal pore in ion permeation.  Amino terminal residues are involved in lipid, cholesterol and lipid raft regulation of P2X1 (Allsopp et al. 2010).

P2X2 has a voltage-dependent gating property even though it lacks a canonical voltage sensor. It is a trimer in which each subunit has two transmembrane helices and a large extracellular domain. The three inter-subunit ATP binding sites are linked to the pore forming transmembrane (TM) domains by beta-strands.  Structural rearrangements of the linker region of the P2X2 receptor channel are induced not only by ligand binding but also by membrane potential change (Keceli and Kubo 2014). Knowledge about P2X receptor activation, especially focusing on the mechanisms underlying ATP-binding, conformational changes in the extracellular domain, and channel gating and desensitization, has been reviewed (Kawate 2017).

Ectodomain shedding of integral membrane receptors results in the release of soluble molecules and modification of the transmembrane regions of these receptors to mediate or modulate extracellular and intracellular signalling. Ectodomain shedding is stimulated by a variety of mechanisms, including the activation of P2 receptors by extracellular nucleotides.  P2 receptor-mediated shedding involves P2 receptors, P2X7 (TC# 1.A.7.1.3) and P2Y2 (TC# 9.A.14.13.16), and the sheddases, ADAM10 (Meprin A, 701 aas and 2 TMSs, N- and C-termini; Q16820) and ADAM17 (Disintegrin, 824 aas and 2 TMSs near the N- and C-termini; P78536; see subfamily 2 in TC Family 9.B.87) (Pupovac and Sluyter 2016). 

The trimeric ATP-gated ion channel, the P2X receptor, has six TMSs, and three of them, the M2 helices, line the ion conduction pathway. Using molecular dynamics simulation, Li 2018 identified four conformational states of the TM domain that are associated with four types of packing between M2 helices. Packing in the extracellular half of the M2 helix produces closed conformations, while packing in the intracellular half produces both open and closed conformations. State transition is observed and supports a mechanism where iris-like twisting of the M2 helices switches the location of helical packing between the extracellular and intracellular halves of the helices. This twisting motion alters the position and orientation of residue side-chains relative to the pore and thereby influences the pore geometry and possibly ion permeation. Helical packing, on the other hand, may restrict the twisting motion and generate discrete conformational states (Li 2018). 

P2X7 receptors are exceptionally versatile: in their canonical role they act as ATP-gated calcium channels and facilitate calcium-signaling cascades, exerting control over the cell via calcium-encoded sensory proteins and transcription factor activation. P2X7 also mediates transmembrane pore formation to regulate cytokine release and facilitate extracellular communication, and when persistently stimulated by high extracellular ATP levels, large P2X7 pores form, which induce apoptotic cell death through cytosolic ion dysregulation. As a scavenger receptor, P2X7 directly facilitates phagocytosis of the cellular debris that arises during neurogenesis (Leeson et al. 2019). P2X7 receptors amplify CNS damage in neurodegenerative diseases (Illes 2020).

In response to extracellular ATP, the purinergic receptor P2X7 mediates various biological processes, including phosphatidylserine (PtdSer) exposure, phospholipid scrambling, dye uptake, ion transport, and interleukin (IL)-1beta production. A transmembrane protein, 'Essential for reactive oxygen species' (Eros) is a necessary protein for P2X7 expression (Ryoden et al. 2020). An Eros-null mouse T cell line lost the ability to expose PtdSer, to scramble phospholipids, and to internalize a dye, YO-PRO-1, and Ca2+. The eros-null mutation abolished the ability of macrophages to secrete IL-1beta in response to ATP. Eros is localized to the endoplasmic reticulum and functions as a chaperone for NADPH oxidase components. Similarly, Eros at the endoplasmic reticulum transiently associates with P2X7 to promote the formation of a stable homotrimeric complex of P2X7. Thus, Eros acts as a chaperone not only for NADPH oxidase, but also for P2X7, and it contributes to the innate immune reaction (Ryoden et al. 2020).

The known seven mammalian receptor (R) subunits (P2X1-7) form cationic channels gated by ATP. Three subunits compose a receptor-channel. Each subunit is a polypeptide consisting of two TMSs (TMS1 and TMS2), intracellular N- and C-termini, and a bulky extracellular loop. Crystallization allowed the identification of the 3D-structure and gating cycle of P2XRs (Illes et al. 2020). The agonist binding pocket is located at the intersection of two neighboring subunits. In addition to the mammalian P2XRs, their primitive ligand-gated counterparts with little structural similarity have been cloned. Medicinal chemistry supplied a range of subtype selective antagonists as well as positive and negative allosteric modulators. Knockout mice and selective antagonists helped to identify pathological functions due to defective P2XRs, such as male infertility (P2X1), hearing loss (P2X2), pain/cough (P2X3), neuropathic pain (P2X4), inflammatory bone loss (P2X5), and faulty immune reactions (P2X7) (Illes et al. 2020). P2X6 acts as a physiological regulator of P2X4 receptor functions when the two receptors form heteroreceptors (Padilla et al. 2016). Also, P2X2/P2X4/P2X6 heterotrimeric receptors can occur (Antonio et al. 2014).

Seven subtypes of P2X receptor channels have been identified in mammals that can form both homomeric and heteromeric channels. P2X1-4 and P2X7 receptor channels are cation-selective, whereas P2X5 has been reported to have both cation and anion permeability. P2X receptor channel structures reveal that each subunit is comprised of two transmembrane helices, with both N-and C-termini on the intracellular side of the membrane and a large extracellular domain that contains the ATP binding sites at subunit interfaces. Structures of ATP-bound P2X receptors with the activation gate open revealed the presence of a cytoplasmic cap over the central ion permeation pathway, leaving lateral fenestrations that may be largely buried within the membrane as potential pathways for ions to permeate the intracellular end of the pore. Tam et al. 2023 identified a critical residue within the intracellular lateral fenestrations that is readily accessible to thiol-reactive compounds from both sides of the membrane and where substitutions influence the relative permeability of the channel to cations and anions. Thus, ions can enter or exit the internal pore through lateral fenestrations that play a critical role in determining the ion selectivity of P2X receptor channels.

Macropore formation and current facilitation are intriguing phenomena associated with ATP-gated P2X7 receptors (P2X7). Macropores are large pores formed in the cell membrane that allow the passage of large molecules. Evidence suggests two alternative pathways: direct entry through the P2X7 pore itself, and an indirect pathway triggered by P2X7 activation involving additional proteins, such as TMEM16F channel/scramblase. On the other hand, current facilitation refers to the progressive increase in current amplitude and activation kinetics observed with prolonged or repetitive exposure to ATP. Various mechanisms, including the activation of chloride channels and intrinsic properties of P2X7, have been proposed to explain this phenomenon. Cevoli et al. 2023 presented an overview of P2X7 current facilitation and macropore formation, proposing mechanistic models that may offer fresh insights into these processes.

The generalized transport reaction is:

Me+ (out) Me+ (in).



This family belongs to the ENaC/P2X Superfamily.

 

References:

and Li GH. (2015). Geometric rules of channel gating inferred from computational models of the P2X receptor transmembrane domain. J Mol Graph Model. 61:107-114.

Acuña-Castillo, C., A. Escobar, M. García-Gómez, V.C. Bachelet, J.P. Huidobro-Toro, D. Sauma, and C. Barrera-Avalos. (2024). P2X7 Receptor in Dendritic Cells and Macrophages: Implications in Antigen Presentation and T Lymphocyte Activation. Int J Mol Sci 25:.

Alexander, S.P.H. and J.A. Peters. (1997). Receptor and ion channel nomenclature supplement. Trends Pharmacol. Sci. 18: 65-68.

Allsopp, R.C. and R.J. Evans. (2011). The Intracellular Amino Terminus Plays a Dominant Role in Desensitization of ATP-gated P2X Receptor Ion Channels. J. Biol. Chem. 286: 44691-44701.

Allsopp, R.C., S. El Ajouz, R. Schmid, and R.J. Evans. (2011). Cysteine scanning mutagenesis (residues Glu52-Gly96) of the human P2X1 receptor for ATP: mapping agonist binding and channel gating. J. Biol. Chem. 286: 29207-29217.

Allsopp, R.C., U. Lalo, and R.J. Evans. (2010). Lipid raft association and cholesterol sensitivity of P2X1-4 receptors for ATP: chimeras and point mutants identify intracellular amino-terminal residues involved in lipid regulation of P2X1 receptors. J. Biol. Chem. 285: 32770-32777.

Antonio, L.S., A.P. Stewart, W.A. Varanda, and J.M. Edwardson. (2014). Identification of P2X2/P2X4/P2X6 heterotrimeric receptors using atomic force microscopy (AFM) imaging. FEBS Lett. 588: 2125-2128.

Aquino, P.E.A., E.A. Siqueira, L.C.F. Paes, E.P. Magalhães, T.M. Barbosa, M.A.J. Carvalho, F.V.C.S. Azul, I.R. Lustosa, M. Mottin, T.L. Sampaio, A.M.C. Martins, E.R. Silveira, and G.S.B. Viana. (2022). N-Methyl-(2S, 4R)-trans-4-hydroxy-L-proline, the major bioactive compound from Sideroxylon obtusifolium, attenuates pilocarpine-induced injury in cultured astrocytes. Braz J Med Biol Res 55: e12381.

Aschrafi, A., S. Sadtler, C. Niculescu, J. Rettinger, and G. Schmalzing. (2004). Trimeric architecture of homomeric P2X2 and heteromeric P2X1+2 receptor subtypes. J. Mol. Biol. 342: 333-343.

Baines, A., K. Parkinson, J.A. Sim, L. Bragg, C.R. Thompson, and R.A. North. (2013). Functional properties of five Dictyostelium discoideum P2X receptors. J. Biol. Chem. 288: 20992-21000.

Bennetts, F.M., H. Venugopal, A. Glukhova, J.I. Mobbs, S. Ventura, and D.M. Thal. (2024). Structural insights into the human P2X1 receptor and ligand interactions. Nat Commun 15: 8418.

Bernier, L.P., D. Blais, E. Boué-Grabot, and P. Séguéla. (2012). A Dual Polybasic Motif Determines Phosphoinositide Binding and Regulation in the P2X Channel Family. PLoS One 7: e40595.

Bianchi, C., B. Alvarez-Castelao, &.#.1.9.3.;. Sebastián-Serrano, C. Di Lauro, L. Soria-Tobar, A. Nicke, T. Engel, and M. Díaz-Hernández. (2023). P2X7 receptor inhibition ameliorates ubiquitin-proteasome system dysfunction associated with Alzheimer''s disease. Alzheimers Res Ther 15: 105.

Bin Dayel, A.F., A.S. Alonazi, T.K. Alshammari, and N.M. Alrasheed. (2023). P2X7 purinergic receptor: A potential target in heart diseases (Review). Mol Med Rep 27:.

Browne, L.E., L. Cao, H.E. Broomhead, L. Bragg, W.J. Wilkinson, and R.A. North. (2011). P2X receptor channels show threefold symmetry in ionic charge selectivity and unitary conductance. Nat Neurosci 14: 17-18.

Browne, L.E., V. Compan, L. Bragg, and R.A. North. (2013). P2X7 receptor channels allow direct permeation of nanometer-sized dyes. J. Neurosci. 33: 3557-3566.

Brünings, X., R. Schmauder, R. Mrowka, K. Benndorf, and C. Sattler. (2024). Subtype-Specific Ligand Binding and Activation Gating in Homomeric and Heteromeric P2X Receptors. Biomolecules 14:.

Burnstock, G. and C. Kennedy. (2011). P2X receptors in health and disease. Adv Pharmacol 61: 333-372.

Caseley, E.A., S.P. Muench, and L.H. Jiang. (2016). Conformational changes during human P2X7 receptor activation examined by structural modelling and cysteine-based cross-linking studies. Purinergic Signal. [Epub: Ahead of Print]

Cevoli, F., B. Arnould, F.A. Peralta, and T. Grutter. (2023). Untangling Macropore Formation and Current Facilitation in P2X7. Int J Mol Sci 24:.

Coddou C., Yan Z. and Stojilkovic SS. (2015). Role of domain calcium in purinergic P2X2 receptor channel desensitization. Am J Physiol Cell Physiol. 308(9):C729-36.

Coddou, C., Z. Yan, T. Obsil, J.P. Huidobro-Toro, and S.S. Stojilkovic. (2011). Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63: 641-683.

Dal Ben, D., M. Buccioni, C. Lambertucci, G. Marucci, A. Thomas, and R. Volpini. (2015). Purinergic P2X receptors: structural models and analysis of ligand-target interaction. Eur J Med Chem 89: 561-580.

Davies, D.L., L. Asatryan, S.T. Kuo, J.J. Woodward, B.F. King, R.L. Alkana, C. Xiao, J.H. Ye, H. Sun, L. Zhang, X.Q. Hu, V. Hayrapetyan, D.M. Lovinger, and T.K. Machu. (2006). Effects of ethanol on adenosine 5''-triphosphate-gated purinergic and 5-hydroxytryptamine receptors. Alcohol Clin Exp Res 30: 349-358.

de Souza CA., Teixeira PC., Faria RX., Krylova O., Pohl P. and Alves LA. (2012). A consensus segment in the M2 domain of the hP2X(7) receptor shows ion channel activity in planar lipid bilayers and in biological membranes. Biochim Biophys Acta. 1818(1):64-71.

de Torre-Minguela, C., M. Barberà-Cremades, A.I. Gómez, F. Martín-Sánchez, and P. Pelegrín. (2016). Macrophage activation and polarization modify P2X7 receptor secretome influencing the inflammatory process. Sci Rep 6: 22586.

Di Virgilio, F., A.L. Giuliani, V. Vultaggio-Poma, S. Falzoni, and A.C. Sarti. (2018). Non-nucleotide Agonists Triggering P2X7 Receptor Activation and Pore Formation. Front Pharmacol 9: 39.

Di Virgilio, F., V. Vultaggio-Poma, S. Falzoni, and A.L. Giuliani. (2023). The Coming of Age of the P2X7 Receptor in Diagnostic Medicine. Int J Mol Sci 24:.

Du J., Dong H. and Zhou HX. (2012). Size matters in activation/inhibition of ligand-gated ion channels. Trends Pharmacol Sci. 33(9):482-93.

Du, J., H. Dong, and H.X. Zhou. (2012). Gating mechanism of a P2X4 receptor developed from normal mode analysis and molecular dynamics simulations. Proc. Natl. Acad. Sci. USA 109: 4140-4145.

Durner, A., E. Durner, and A. Nicke. (2023). Improved ANAP incorporation and VCF analysis reveals details of P2X7 current facilitation and a limited conformational interplay between ATP binding and the intracellular ballast domain. Elife 12:. [Epub: Ahead of Print]

Engel, T. (2023). The P2X7 Receptor as a Mechanistic Biomarker for Epilepsy. Int J Mol Sci 24:.

Fabbretti E. and Nistri A. (2012). Regulation of P2X3 receptor structure and function. CNS Neurol Disord Drug Targets. 11(6):687-98.

Fang, M. and R. Lai. (2024). The price of P2X7R freedom is neuroinflammation. Immunity 57: 401-403.

Feng, Y.H., X. Li, L. Wang, L. Zhou, and G.I. Gorodeski. (2006). A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J. Biol. Chem. 281: 17228-17237.

Feske, S., F. Colucci, and W.A. Coetzee. (2024). Do K channels have a role in immunity? Front Immunol 15: 1484971.

Fountain, S.J., K. Parkinson, M.T. Young, L. Cao, C.R. Thompson, and R.A. North. (2007). An intracellular P2X receptor required for osmoregulation in Dictyostelium discoideum. Nature. 448: 200-203.

Fountain, S.J., L. Cao, M.T. Young, and R.A. North. (2008). Permeation Properties of a P2X Receptor in the Green Algae Ostreococcus tauri. J. Biol. Chem. 283: 15122-15126.

Franklin, K.M., L. Asatryan, M.W. Jakowec, J.R. Trudell, R.L. Bell, and D.L. Davies. (2014). P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. Front Neurosci 8: 176.

Gao C., Yu Q., Xu H., Zhang L., Liu J., Jie Y., Ma W., Samways DS. and Li Z. (2015). Roles of the lateral fenestration residues of the P2X(4) receptor that contribute to the channel function and the deactivation effect of ivermectin. Purinergic Signal. 11(2):229-38.

Gao, X.F., J.F. Feng, W. Wang, Z.H. Xiang, X.J. Liu, C. Zhu, Z.X. Tang, X.Z. Dong, and C. He. (2015). Pirt reduces bladder overactivity by inhibiting purinergic receptor P2X3. Nat Commun 6: 7650.

George, B., K.J. Swartz, and M. Li. (2019). Hearing loss mutations alter the functional properties of human P2X2 receptor channels through distinct mechanisms. Proc. Natl. Acad. Sci. USA 116: 22862-22871.

Habermacher, C., A. Martz, N. Calimet, D. Lemoine, L. Peverini, A. Specht, M. Cecchini, and T. Grutter. (2016). Photo-switchable tweezers illuminate pore-opening motions of an ATP-gated P2X ion channel. Elife 5:.

Hattori M. and Gouaux E. (2012). Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 485(7397):207-12.

He, Y.Q., J. Chen, X.J. Lu, and Y.H. Shi. (2013). Characterization of P2X7R and its function in the macrophages of ayu, Plecoglossus altivelis. PLoS One 8: e57505.

Hirayama, Y., H.P.N. Le, H. Hashimoto, I. Ishii, S. Koizumi, and N. Anzai. (2024). Preconditioning-induced facilitation of lactate release from astrocytes is essential for brain ischemic tolerance. eNeuro. [Epub: Ahead of Print]

Illes, P. (2020). P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases. Int J Mol Sci 21:.

Illes, P., C.E. Müller, K.A. Jacobson, T. Grutter, A. Nicke, S.J. Fountain, C. Kennedy, G. Schmalzing, M.F. Jarvis, S.S. Stojilkovic, B.F. King, and F. Di Virgilio. (2020). Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol. [Epub: Ahead of Print]

Ilyaskin, A.V., F. Sure, V. Nesterov, S. Haerteis, and C. Korbmacher. (2019). Bile acids inhibit human purinergic receptor P2X4 in a heterologous expression system. J Gen Physiol. [Epub: Ahead of Print]

Jacobson, K.A. and D. Salvemini. (2023). Editorial: Small molecules and biologics for future purinergic therapeutics. Purinergic Signal 19: 465-466.

Janks, L., R.S. Sprague, and T.M. Egan. (2019). ATP-Gated P2X7 Receptors Require Chloride Channels To Promote Inflammation in Human Macrophages. J Immunol 202: 883-898.

Jelínkova, I., V. Vávra, M. Jindrichova, T. Obsil, H.W. Zemkova, H. Zemkova, and S.S. Stojilkovic. (2008). Identification of P2X(4) receptor transmembrane residues contributing to channel gating and interaction with ivermectin. Pflugers Arch 456: 939-950.

Jiang, L.H., F. Rassendren, A. Surprenant, and R.A. North. (2000). Identification of amino acid residues contributing to the ATP-binding site of a purinergic P2X receptor. J. Biol. Chem. 275: 34190-34196.

Jindrichova M., Bhattacharya A., Rupert M., Skopek P., Obsil T. and Zemkova H. (2015). Functional characterization of mutants in the transmembrane domains of the rat P2X7 receptor that regulate pore conductivity and agonist sensitivity. J Neurochem. 133(6):815-27.

Jindrichova, M., K. Khafizov, A. Skorinkin, D. Fayuk, G. Bart, H. Zemkova, and R. Giniatullin. (2011). Highly conserved tyrosine 37 stabilizes desensitized states and restricts calcium permeability of ATP-gated P2X3 receptor. J Neurochem 119: 676-685.

Kannan, P., M.P. Nanda Kumar, N. Rathinam, D.T. Kumar, and M. Ramasamy. (2023). Elucidating the mutational impact in causing Niemann-Pick disease type C: an approach. J Biomol Struct Dyn 41: 8561-8570.

Karasawa, A., K. Michalski, P. Mikhelzon, and T. Kawate. (2017). The P2X7 receptor forms a dye-permeable pore independent of its intracellular domain but dependent on membrane lipid composition. Elife 6:.

Kawate, T. (2017). P2X Receptor Activation. Adv Exp Med Biol. [Epub: Ahead of Print]

Kawate, T., J.C. Michel, W.T. Birdsong, and E. Gouaux. (2009). Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature 460: 592-598.

Kawate, T., J.L. Robertson, M. Li, S.D. Silberberg, and K.J. Swartz. (2011). Ion access pathway to the transmembrane pore in P2X receptor channels. J Gen Physiol 137: 579-590.

Keceli B. and Kubo Y. (2014). Voltage- and ATP-dependent structural rearrangements of the P2X2 receptor associated with the gating of the pore. J Physiol. 592(Pt 21):4657-76.

Khalafalla, M.G., L.T. Woods, J.M. Camden, A.A. Khan, K.H. Limesand, M.J. Petris, L. Erb, and G.A. Weisman. (2017). P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy. J. Biol. Chem. [Epub: Ahead of Print]

Kracun S., Chaptal V., Abramson J. and Khakh BS. (2010). Gated access to the pore of a P2X receptor: structural implications for closed-open transitions. J Biol Chem. 285(13):10110-21.

Kristof, Z., Z. Gal, D. Torok, N. Eszlari, S. Sutori, B. Erdelyi-Hamza, P. Petschner, B. Sperlagh, I.M. Anderson, J.F.W. Deakin, G. Bagdy, G. Juhasz, and X. Gonda. (2023). Variation along P2RX7 interacts with early traumas on severity of anxiety suggesting a role for neuroinflammation. Sci Rep 13: 7757.

Lara, R., E. Adinolfi, C.A. Harwood, M. Philpott, J.A. Barden, F. Di Virgilio, and S. McNulty. (2020). P2X7 in Cancer: From Molecular Mechanisms to Therapeutics. Front Pharmacol 11: 793.

Latapiat, V., F.E. Rodríguez, F. Godoy, F.A. Montenegro, N.P. Barrera, and J.P. Huidobro-Toro. (2017). P2X4 Receptorand Electrophysiological Approaches Reveal Insights of Ivermectin and Zinc Allosteric Modulation. Front Pharmacol 8: 918.

Lataro, R.M., D.J.A. Moraes, F.N. Gava, A.C.M. Omoto, C.A.A. Silva, F. Brognara, L. Alflen, V. Brazão, R.P. Colato, J.C. do Prado, Jr, A.P. Ford, H.C. Salgado, and J.F.R. Paton. (2023). P2X3 receptor antagonism attenuates the progression of heart failure. Nat Commun 14: 1725.

Leeson, H.C., M.A. Kasherman, T. Chan-Ling, M.D. Lovelace, J.C. Brownlie, K.M. Toppinen, B.J. Gu, and M.W. Weible, 2nd. (2018). P2X7 Receptors Regulate Phagocytosis and Proliferation in Adult Hippocampal and SVZ Neural Progenitor Cells: Implications for Inflammation in Neurogenesis. Stem Cells. [Epub: Ahead of Print]

Leeson, H.C., T. Chan-Ling, M.D. Lovelace, J.C. Brownlie, B.J. Gu, and M.W. Weible. (2019). P2X7 receptor signaling during adult hippocampal neurogenesis. Neural Regen Res 14: 1684-1694.

Li, G.H. (2018). Exploring conformational states and helical packings in the P2X receptor transmembrane domain by molecular dynamics simulation. J Biol Phys. [Epub: Ahead of Print]

Li, M., T. Kawate, S.D. Silberberg, and K.J. Swartz. (2010). Pore-opening mechanism in trimeric P2X receptor channels. Nat Commun 1: 44.

Li, Q., X. Luo, and S. Muallem. (2005). Regulation of the P2X7 receptor permeability to large molecules by extracellular Cl- and Na+. J. Biol. Chem. 280: 26922-26927.

Liang, X., H. Xu, C. Li, S. Yin, T. Xu, J. Liu, and Z. Li. (2013). Functional Identification of Close Proximity Amino Acid Side Chains within the Transmembrane-Spanning Helixes of the P2X2 Receptor. PLoS One 8: e70629.

Lin, Y.Y., Y. Lu, C.Y. Li, X.F. Ma, M.Q. Shao, Y.H. Gao, Y.Q. Zhang, H.N. Jiang, Y. Liu, Y. Yang, L.D. Huang, P. Cao, H.S. Wang, J. Wang, and Y. Yu. (2024). Finely ordered intracellular domain harbors an allosteric site to modulate physiopathological function of P2X3 receptors. Nat Commun 15: 7652.

Liu, H.Y., A.M. Pappa, A. Pavia, C. Pitsalidis, Q. Thiburce, A. Salleo, R.M. Owens, and S. Daniel. (2020). Self-assembly of mammalian cell membranes on bioelectronic devices with functional transmembrane proteins. Langmuir. [Epub: Ahead of Print]

Lu, H., D. Burns, P. Garnier, G. Wei, K. Zhu, and W. Ying. (2007). P2X7 receptors mediate NADH transport across the plasma membranes of astrocytes. Biochem. Biophys. Res. Commun. 362: 946-950.

Ludlow, M.J., L. Durai, and S.J. Ennion. (2009). Functional characterization of intracellular Dictyostelium discoideum P2X receptors. J. Biol. Chem. 284: 35227-35239.

Mager, P.P., A. Weber, and P. Illes. (2004). Bridging the gap between structural bioinformatics and receptor research: the membrane-embedded, ligand-gated, P2X glycoprotein receptor. Curr Top Med Chem 4: 1657-1705.

Mansoor, S.E., W. Lü, W. Oosterheert, M. Shekhar, E. Tajkhorshid, and E. Gouaux. (2016). X-ray structures define human P2X3 receptor gating cycle and antagonist action. Nature. [Epub: Ahead of Print]

Markwardt, F. (2020). Human P2X7 receptors - Properties of single ATP-gated ion channels. Biochem Pharmacol 114307. [Epub: Ahead of Print]

Marques-da-Silva, C., M.M. Chaves, J.C. Rodrigues, S. Corte-Real, R. Coutinho-Silva, and P.M. Persechini. (2011). Differential modulation of ATP-induced P2X7-associated permeabilities to cations and anions of macrophages by infection with Leishmania amazonensis. PLoS One 6: e25356.

Matyśniak, D., M. Oslislok, and P. Pomorski. (2022). P2X7 receptor in normal and cancer cells in the perspective of nucleotide signaling. Acta Biochim Pol. [Epub: Ahead of Print]

Matyśniak, D., N. Nowak, and P. Pomorski. (2020). P2X7 receptor activity landscape in rat and human glioma cell lines. Acta Biochim Pol 67: 7-14.

McCleskey E.W. and M.S. Gold. (1999). Ion channels of nociception. Annu. Rev. Physiol. 61: 835-856.

Minato, Y., S. Suzuki, T. Hara, Y. Kofuku, G. Kasuya, Y. Fujiwara, S. Igarashi, E. Suzuki, O. Nureki, M. Hattori, T. Ueda, and I. Shimada. (2016). Conductance of P2X4 purinergic receptor is determined by conformational equilibrium in the transmembrane region. Proc. Natl. Acad. Sci. USA 113: 4741-4746.

North, R.A. (2002). Molecular physiology of P2X receptors. Physiol. Rev. 82: 1013-1067.

North, R.A. (1996). Families of ion channels with two hydrophobic segments. Curr. Opin. Cell Biol. 8: 474-483.

Pacheco, P.A.F., J.V. Faria, A.C. Silva, N.L. von Ranke, R.C. Silva, C.R. Rodrigues, D.R. da Rocha, and R.X. Faria. (2023). In silico and pharmacological study of N,S-acetal juglone derivatives as inhibitors of the P2X7 receptor-promoted in vitro and in vivo inflammatory response. Biomed Pharmacother 162: 114608.

Padilla, K., D. Gonzalez-Mendoza, L.C. Berumen, J.E. Escobar, R. Miledi, and G. García-Alcocer. (2016). Differential gene expression patterns and colocalization of ATP-gated P2X6/P2X4 ion channels during rat small intestine ontogeny. Gene Expr Patterns 21: 81-88.

Pasqualetto, G., A. Brancale, and M.T. Young. (2018). The Molecular Determinants of Small-Molecule Ligand Binding at P2X Receptors. Front Pharmacol 9: 58.

Pierdominici-Sottile, G., L. Moffatt, and J. Palma. (2016). The Dynamic Behavior of the P2X4 Ion Channel in the Closed Conformation. Biophys. J. 111: 2642-2650.

Pippel, A., M. Stolz, R. Woltersdorf, A. Kless, G. Schmalzing, and F. Markwardt. (2017). Localization of the gate and selectivity filter of the full-length P2X7 receptor. Proc. Natl. Acad. Sci. USA 114: E2156-E2165.

Popova, M., L. Rodriguez, J.R. Trudell, S. Nguyen, M. Bloomfield, D.L. Davies, and L. Asatryan. (2020). Residues in Transmembrane Segments of the P2X4 Receptor Contribute to Channel Function and Ethanol Sensitivity. Int J Mol Sci 21:.

Pupovac, A. and R. Sluyter. (2016). Roles of extracellular nucleotides and P2 receptors in ectodomain shedding. Cell Mol Life Sci. [Epub: Ahead of Print]

Ren, C., Y.K. Mou, X.Y. Song, S.Z. Wei, H.R. Wang, Y. Wang, W.B. Zhang, B. Li, and X.C. Song. (2023). P2X7 receptor of microglia in olfactory bulb mediates the pathogenesis of olfactory dysfunction in a mouse model of allergic rhinitis. FASEB J. 37: e22955.

Reyes-Espinosa, F., M.G. Nieto-Pescador, V. Bocanegra-García, E. Lozano-Guzmán, and G. Rivera. (2020). In Silico Analysis of FDA Drugs as P2X4 Modulators for the Treatment of Alcohol Use Disorder. Mol Inform. [Epub: Ahead of Print]

Rodionova, I.A., F. Heidari Tajabadi, Z. Zhang, D.A. Rodionov, and M.H. Saier, Jr. (2019). A Riboflavin Transporter in Bdellovibrio exovorous JSS. J. Mol. Microbiol. Biotechnol. 1-8. [Epub: Ahead of Print]

Roger, S., P. Pelegrin, and A. Surprenant. (2008). Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding. J. Neurosci. 28: 6393-6401.

Rokic, M.B., S.S. Stojilkovic, V. Vavra, P. Kuzyk, V. Tvrdonova, and H. Zemkova. (2013). Multiple Roles of the Extracellular Vestibule Amino Acid Residues in the Function of the Rat P2X4 Receptor. PLoS One 8: e59411.

Rokic, M.B., V. Tvrdoňová, V. Vávra, M. Jindřichová, T. Obšil, S.S. Stojilkovic, and H. Zemková. (2010). Roles of conserved ectodomain cysteines of the rat P2X4 purinoreceptor in agonist binding and channel gating. Physiol Res 59: 927-935.

Rupert, C., C.D. Aversana, L. Mosca, V. Montanaro, D. Arcaniolo, M. De Sio, A. Bilancio, L. Altucci, W. Palinski, R. Pili, and F. de Nigris. (2023). Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models. J Exp Clin Cancer Res 42: 134.

Rupert, M., A. Bhattacharya, S. Sivcev, M. Knezu, J. Cimicka, and H. Zemkova. (2023). Identification of residues in the first transmembrane domain of the P2X7 that regulate receptor trafficking, sensitization and dye uptake function. J Neurochem. [Epub: Ahead of Print]

Rupert, M., A. Bhattacharya, V.T. Stillerova, M. Jindrichova, A. Mokdad, E. Boué-Grabot, and H. Zemkova. (2020). Role of Conserved Residues and F322 in the Extracellular Vestibule of the Rat P2X7 Receptor in Its Expression, Function and Dye Uptake Ability. Int J Mol Sci 21:.

Ryoden, Y., T. Fujii, K. Segawa, and S. Nagata. (2020). Functional Expression of the P2X7 ATP Receptor Requires Eros. J Immunol 204: 559-568.

Sadovnick, A.D., B.J. Gu, A.L. Traboulsee, C.Q. Bernales, M. Encarnacion, I.M. Yee, M.G. Criscuoli, X. Huang, A. Ou, C.J. Milligan, S. Petrou, J.S. Wiley, and C. Vilariño-Güell. (2017). Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis. Hum Mutat. [Epub: Ahead of Print]

Salahuddin, M.M., G.A. Omran, M.W. Helmy, and M.E. Houssen. (2021). Effect of Regorafenib on P2X7 Receptor Expression and Different Oncogenic Signaling Pathways in a Human Breast Cancer Cell Line: A Potential of New Insight of the Antitumor Effects of Regorafenib. Curr Issues Mol Biol 43: 2199-2209.

Samways DS., Khakh BS. and Egan TM. (2012). Allosteric Modulation of Ca2+ flux in Ligand-gated Cation Channel (P2X4) by Actions on Lateral Portals. J Biol Chem. 287(10):7594-602.

Samways, D.S., B.S. Khakh, S. Dutertre, and T.M. Egan. (2011). Preferential use of unobstructed lateral portals as the access route to the pore of human ATP-gated ion channels (P2X receptors). Proc. Natl. Acad. Sci. USA 108: 13800-13805.

Schäfer, W., T. Stähler, C. Pinto Espinoza, W. Danquah, J.H. Knop, B. Rissiek, F. Haag, and F. Koch-Nolte. (2022). Origin, distribution, and function of three frequent coding polymorphisms in the gene for the human P2X7 ion channel. Front Pharmacol 13: 1033135.

Schwarz, N., L. Drouot, A. Nicke, R. Fliegert, O. Boyer, A.H. Guse, F. Haag, S. Adriouch, and F. Koch-Nolte. (2012). Alternative splicing of the N-terminal cytosolic and transmembrane domains of P2X7 controls gating of the ion channel by ADP-ribosylation. PLoS One 7: e41269.

Shibata, M., E. Ishizaki, T. Zhang, M. Fukumoto, A. Barajas-Espinosa, T. Li, and D.G. Puro. (2018). Purinergic Vasotoxicity: Role of the Pore/Oxidant/K Channel/Ca Pathway in P2X-Induced Cell Death in Retinal Capillaries. Vision (Basel) 2:.

Silberberg, S.D., T.H. Chang, and K.J. Swartz. (2005). Secondary structure and gating rearrangements of transmembrane segments in rat P2X4 receptor channels. J Gen Physiol 125: 347-359.

Sivcev, S., B. Slavikova, M. Ivetic, M. Knezu, E. Kudova, and H. Zemkova. (2020). Lithocholic acid inhibits P2X2 and potentiates P2X4 receptor channel gating. J Steroid Biochem Mol Biol 105725. [Epub: Ahead of Print]

Sivcev, S., E. Kudova, and H. Zemkova. (2023). Neurosteroids as positive and negative allosteric modulators of ligand-gated ion channels: P2X receptor perspective. Neuropharmacology 234: 109542.

Skarratt, K.K., B.J. Gu, M.D. Lovelace, C.J. Milligan, L. Stokes, R. Glover, S. Petrou, J.S. Wiley, and S.J. Fuller. (2020). A P2RX7 single nucleotide polymorphism haplotype promotes exon 7 and 8 skipping and disrupts receptor function. FASEB J. [Epub: Ahead of Print]

Smart, M.L., B. Gu, R.G. Panchal, J. Wiley, B. Cromer, D.A. Williams, and S. Petrou. (2003). P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J. Biol. Chem. 278: 8853-8860.

Soto, F., M. Garcia-Guzman, and W. Stühmer. (1997). Cloned ligand-gated channels activated by extracellular ATP (P2X receptors). J. Membr. Biol. 160: 91-100.

Stojilkovic, S.S., Z. Yan, T. Obsil, and H. Zemkova. (2010). Structural insights into the function of P2X4: an ATP-gated cation channel of neuroendocrine cells. Cell Mol Neurobiol 30: 1251-1258.

Sugiyama, T., M. Kobayashi, H. Kawamura, Q. Li, D.G. Puro, and M. Kobayshi. (2004). Enhancement of P2X(7)-induced pore formation and apoptosis: an early effect of diabetes on the retinal microvasculature. Invest Ophthalmol Vis Sci 45: 1026-1032.

Sun, L.F., Y. Liu, J. Wang, L.D. Huang, Y. Yang, X.Y. Cheng, Y.Z. Fan, M.X. Zhu, H. Liang, Y. Tian, H.S. Wang, C.R. Guo, and Y. Yu. (2019). Altered allostery of the left flipper domain underlies the weak ATP response of rat P2X5 receptors. J. Biol. Chem. 294: 19589-19603.

Sun, S., D. Gong, R. Liu, R. Wang, D. Chen, T. Yuan, S. Wang, C. Xing, Y. Lv, G. Du, and L. Fang. (2023). Puerarin Inhibits NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis via P2X7 Receptor in Cardiomyocytes and Macrophages. Int J Mol Sci 24:.

Tam, S.W., K. Huffer, M. Li, and K.J. Swartz. (2023). Ion permeation pathway within the internal pore of P2X receptor channels. Elife 12:.

Townsend-Nicholson, A., B.F. King, S.S. Wildman, and G. Burnstock. (1999). Molecular cloning, functional characterization and possible cooperativity between the murine P2X4 and P2X4a receptors. Brain Res Mol Brain Res 64: 246-254.

Vial, C., J.A. Roberts, and R.J. Evans. (2004). Molecular properties of ATP-gated P2X receptor ion channels. Trends Pharmacol Sci 25: 487-493.

Wanasuntronwong, A., S. Kaewsrisung, N. Lakkhanachatpan, R. Meepong, T. Arayapisit, and M. Tantisira. (2024). Standardized Centella asiatica extract ECa 233 alleviates pain hypersensitivity by modulating P2X3 in trigeminal neuropathic pain. J Appl Oral Sci 32: e20230337.

Wann, S.R., H.R. Lo, Y.T. Chang, J.B. Liao, Z.H. Wen, and P.L. Chi. (2023). P2X7 receptor blockade reduces pyroptotic inflammation and promotes phagocytosis in Vibrio vulnificus infection. J Cell Physiol. [Epub: Ahead of Print]

Wen, H. and R.J. Evans. (2011). Contribution of the intracellular C terminal domain to regulation of human P2X1 receptors for ATP by phorbol ester and Gq coupled mGlu(1α) receptors. Eur J Pharmacol 654: 155-159.

Zech, A., B. Wiesler, C.K. Ayata, T. Schlaich, T. Dürk, M. Hoßfeld, N. Ehrat, S. Cicko, and M. Idzko. (2016). P2rx4 deficiency in mice alleviates allergen-induced airway inflammation. Oncotarget 7: 80288-80297.

Zelentsova, A.S., A.V. Deykin, V.O. Soldatov, A.A. Ulezko, A.Y. Borisova, V.S. Belyaeva, M.Y. Skorkina, and P.R. Angelova. (2022). P2X7 Receptor and Purinergic Signaling: Orchestrating Mitochondrial Dysfunction in Neurodegenerative Diseases. eNeuro 9:.

Zemkova H., Khadra A., Rokic MB., Tvrdonova V., Sherman A. and Stojilkovic SS. (2015). Allosteric regulation of the P2X4 receptor channel pore dilation. Pflugers Arch. 467(4):713-26.

Zhang, C.M., X. Huang, H.L. Lu, X.M. Meng, N.N. Song, L. Chen, Y.C. Kim, J. Chen, and W.X. Xu. (2019). Diabetes-induced damage of gastric nitric oxide neurons mediated by P2X7R in diabetic mice. Eur J Pharmacol 851: 151-160. [Epub: Ahead of Print]

Examples:

TC#NameOrganismal TypeExample
1.A.7.1.1

ATP-gated cation channel (purinoceptor or ATP-neuroreceptor). Residues Glu52-Gly96 play roles in agonist binding and channel gating (Allsopp et al., 2011).  The rat protein is 89% identical to the human ortholog. Mutations likely to confer ivermectin sensitivity to human P2X1 have been proposed (Pasqualetto et al. 2018).  The P2X1 receptor is a trimeric ligand-gated ion channel that plays an important role in urogenital and immune functions. Bennetts et al. 2024 employed cryogenic electron microscopy (cryo-EM) to elucidate the structures of the P2X1 receptor in an ATP-bound desensitised state and an NF449-bound closed state. NF449, a potent P2X1 receptor antagonist, engages the receptor distinctively, while ATP, the endogenous ligand, binds in a manner consistent with other P2X receptors. To explore the molecular basis of receptor inhibition, activation, and ligand interactions, key residues involved in ligand and metal ion binding were mutated. Radioligand binding assays with [3H]-α,β-methylene ATP and intracellular calcium ion influx assays were used to evaluate the effects of these mutations. These experiments validated key ligand-receptor interactions and identified conserved and non-conserved residues critical for ligand binding or receptor modulation (Bennetts et al. 2024). 

Animals

P2X1 of Homo sapiens

 
1.A.7.1.10

Green algal ATP-gated cation channel receptor P2X4 of 384 aas, 2 TMSs (Fountain et al., 2008).

Eukaryotes

P2X4 of Ostreococcus lucimarinus

 
1.A.7.1.11

P2X5 ATP-activated receptor, P2X5R or P2RX5, of 422 aas and 2 TMSs, N- and C-terminal (Sun et al. 2019). This receptor can transport both cations and anions, in contrast to most other P2X channels (Tam et al. 2023).

P2X5R of Homo sapiens

 
1.A.7.1.12

P2X7 purinoceptor of 595 aas and 2 TMSs. All residues that are conserved among the P2X receptor subtypes respond to alanine mutagenesis with an inhibition (Y51, Q52, and G323) or a significant decrease (K49, G326, K327, and F328) of 2',3'-O-(benzoyl-4-benzoyl)-ATP (BzATP)-induced current and permeability to ethidium bromide, while the nonconserved residue (F322), which is also present in P2X4 receptors, responds with a 10-fold higher sensitivity to BzATP, much slower deactivation kinetics, and a higher propensity to form the large dye-permeable pore. Rupert et al. 2020 examined the membrane expression of conserved mutants and found that Y51, Q52, G323, and F328 play a role in the trafficking of the receptor to the plasma membrane, while K49 controls receptor responsiveness to agonists. The K49R, F322Y, F322W, and F322L mutants reversed the receptor function, indicating that positively charged and large hydrophobic residues are important at positions 49 and 322, respectively. Thus, clusters of conserved residues above the transmembrane domain 1 (K49-Y51-Q52) and transmembrane domain 2 (G326-K327-F328) are important for receptor structure, membrane expression, and channel gating and that the nonconserved residue (F322) at the top of the extracellular vestibule is involved in hydrophobic inter-subunit interaction which stabilizes the closed state of the P2X7 receptor channel (Rupert et al. 2020). This protein is 80% identical to the human ortholog (TC# 1.A.7.1.3). The P2X7 receptor in normal and cancer cells, in the perspective of nucleotide signaling, has been reviewed (Matyśniak et al. 2022). N-Methyl-(2S, 4R)-trans-4-hydroxy-L-proline, the major bioactive compound from Sideroxylon obtusifolium, attenuates pilocarpine-induced injury in cultured astrocytes. The improvement of ROS accumulation, VDAC-1 overexpression, and mitochondrial depolarization are possible mechanisms of the NMP protective action on reactive astrocytes (Aquino et al. 2022). The large intracellular C-terminus of the pro-inflammatory P2X7 ion channel receptor (P2X7R) is associated with diverse P2X7R-specific functions. Cryo-EM structures of the closed and ATP-bound open full-length P2X7R identified a membrane-associated anchoring domain, an open-state stabilizing 'cap' domain, and a globular 'ballast domain' containing GTP/GDP and dinuclear Zn2+-binding sites with unknown functions. To investigate protein dynamics during channel activation, Durner et al. 2023 incorporated the environment-sensitive fluorescent unnatural amino acid, L-3-(6-acetylnaphthalen-2-ylamino)-2-aminopropanoic acid (ANAP) into Xenopus laevis oocyte-expressed P2X7Rs and performed voltage clamp fluorometry (VCF). Predicted conformational changes within the extracellular and the transmembrane domains were confirmed. The ballast domain functions fairly independently of the extracellular ATP binding domain and may require activation by additional ligands and/or protein interactions (Durner et al. 2023).  The P2X7 receptor provides a mechanistic biomarker for epilepsy (Engel 2023). Puerarin inhibits NLRP3-caspase-1-GSDMD-mediated pyroptosis via the P2X7 receptor in cardiomyocytes and macrophages (Sun et al. 2023).


 

P2X7 of Rattus norvegicus (Rat)

 
1.A.7.1.2

ATP-gated cation channel (purinoceptor or ATP-neuroreceptor), P2X2.  His33 and Ser345 are proximal to each other across an intra-subunit interface, and the relative movement between the two TMSs is likely important for transmitting the action of ATP binding to the opening of the channel (Liang et al. 2013).  Two processes contribute to receptor desensitization, one, bath calcium-independent and the other, bath calcium-dependent, the latter being more important (Coddou et al. 2015).  ATP dissociation causes reduction in outer pore expansion compared to the ATP-bound state. Moreover, the inner and outer ends of adjacent pore-lining helices come closer during opening, likely through a hinge-bending motion (Habermacher et al. 2016). Hearing loss mutations alter the functional properties of human P2X2 receptor channels through more than one mechanism (George et al. 2019). Residues in TMSs of the P2X4 receptor that contribute to channel function and ethanol sensitivity have been identified (Popova et al. 2020). Self-assembly of mammalian cell membranes on bioelectronic devices with  P2X2 channel has been achieved (Liu et al. 2020). Lithocholic acid inhibits P2X2 and potentiates P2X4 receptor channel gating (Sivcev et al. 2020).

Animals

P2X2 of Rattus norvegicus

 
1.A.7.1.3

ATP-gated NaCl-regulated nonselective cation (Na+, K+ and Ca2+) channel, the P2X purinoreceptor 7, P2X7, P2RX7 or P2X7R. It expands to accommodate large molecules such as NAD, N-methyl-D-glucamine and triethyl ammonium) (Li et al., 2005; Lu et al., 2007) and plays a role in changing pain thresholds. A region called ADSEG in all P2X receptors is located in the M2 domain which aligns with TMS 5 in VIC Kchannels (1.A.1). ADSEG from P2X(7)R forms cation-selective channels in artificial lipid bilayers and biological membranes similar to those of the full length protein (de Souza et al., 2011). Channel activity is regulated by calmodulin (Roger et al., 2008).  P2XRs allow direct permeation of nanometer-sized dyes (Browne et al. 2013).  Macrophage P2X7 receptors are modulated in response to infection with Leishmania amazonensis so that they become more permeable to anions and less permeable to cations (Marques-da-Silva et al. 2011).  Residues involved in pore conductivity and agonist sensitivity have been identified (Jindrichova et al. 2015) as have residues involved in channel activation (Caseley et al. 2016). The channel opening extends from the pre-TMS2 region through the outer half of the trihelical TMS2 channel; the gate and the selectivity filter have been identified (Pippel et al. 2017). The purinergic receptors, P2RX4 and P2RX7, when mutated, affect susceptibility to multiple sclerosis (MS) (Sadovnick et al. 2017). P2X7 may serve as a receptor for the regulation of annexin secretion during macrophage polarization (de Torre-Minguela et al. 2016). These receptors can reduce salivary gland inflammation (Khalafalla et al. 2017). The P2X7 receptor forms ion channels dependent on lipids but independently of its cytoplasmic domain (Karasawa et al. 2017).  A truncated naturally occurring variant of P2X7, P2X7-j of 258 aas, lacks the entire intracellular carboxyl terminus, the second TMS, and the distal third of the extracellular loops of the full-length P2X7 receptor. P2X7-j, expressed in the plasma membrane, failed to form pores and mediate apoptosis (Feng et al. 2006). P2X7-j formed heterooligomers with and blocked P2X7-mediated channel formation. Alternative splicing of P2X7 controls gating of the ion channel by ADP-ribosylation (Schwarz et al. 2012). Three distinct roles for P2X7 during adult neurogenesis have been demonstrated, and these depend on the extracellular ATP concentrations: (i) P2X7 receptors can form transmembrane pores leading to cell death, (ii) P2X7 receptors can regulate rates of proliferation, likely via calcium signalling, and (iii) P2X7 can function as scavenger receptors in the absence of ATP, allowing neural progenitor cells (NPCs) to phagocytose apoptotic NPCs during neurogenesis (Leeson et al. 2018). P2X7 also plays a role in purinergic vasotoxicity and cell death (Shibata et al. 2018). NAD+ covalently modifies the P2X7R of mouse T lymphocytes, thus lowering the ATP threshold for activation. Other structurally unrelated agents have been reported to activate  P2X7R: (a) the antibiotic polymyxin B, possibly a positive allosteric P2X7R modulator, (b) the bactericidal peptide LL-37, (c) the amyloidogenic β peptide, and (d) serum amyloid A (Di Virgilio et al. 2018). Some agents, such as Alu-RNA, have been suggested to activate P2X7R, acting on the intracellular N- or C-terminal domains. P2X7R of enteric neurons may be involved in diabetes-induced nitrous oxide (NOS) neuron damage via combining with pannexin-1 to form transmembrane pores which transport macromolecular substances and calcium into the cells (Zhang et al. 2019). ATP-gated P2X7 receptors require chloride channels to promote inflammation in human macrophages (Janks et al. 2019). P2X7 overexpression is can be associated with cancer progression. P2X7 plays also an important role in glioma biology (Matyśniak et al. 2020). Upon activation by its main ligand, extracellular ATP, P2X7 can form a nonselective channel for cations to enter the cell, but prolonged activation, via high levels of extracellular ATP over an extended time period can lead to the formation of a macropore, leading to depolarization of the plasma membrane and ultimately to cell death. Thus, dependent on its activation state, P2X7 can either drive cell survival and proliferation, or induce cell death. It is relevant to cancerous growth (Lara et al. 2020). The human P2X7 receptor is a ligand gated ion channel opened by binding of ATP, like the other P2X receptor subtypes. P2X7 receptors become activated under pathological conditions of ATP release like hypoxia or cell destruction. They are involved in inflammatory and nociceptive reactions of the organism to these pathological events. Polar residues of the second TMS of the three protein subunits are important for ion conduction, with S342 constituting the ion selectivity filter and the gate of the channel. The specific long C-terminal domains are important for hP2X7 receptor ion channel function, as their loss strongly decreases ion channel currents (Markwardt 2020). Studies of the enhancement of P2X(7)-induced pore formation and apoptosis revealed an early effect of diabetes on retinal microvasculature; diabetes appears to facilitate the channel-to-pore transition that occurs during activation of these purinoceptors (Sugiyama et al. 2004). Regorafenib exhibits antitumor activity on the breast cancer cell line via modulation of the P2X7/HIF-1alpha/VEGF, P2X7/P38, P2X7/ERK/NF-kappaB, and P2X7/beclin 1 pathways (Salahuddin et al. 2021). The involvement of the P2RX7 purinoreceptor in triggering mitochondrial dysfunction during the development of neurodegenerative disorders has been reviewed (Zelentsova et al. 2022). The P2X7 receptor and purinergic signaling play roles in orchestrating mitochondrial dysfunction in neurodegenerative diseases (Zelentsova et al. 2022). The P2X7 purinergic receptor represents a potential target in heart diseases (Bin Dayel et al. 2023). Conserved and receptor specific TMS1 residues control surface expression of the P2X7 protein, nonpolar residues control receptor sensitization, and D48 regulates intrinsic channel properties (Rupert et al. 2023). The P2X7 receptor of microglia in the olfactory bulb mediates the pathogenesis of olfactory dysfunction in a mouse model of allergic rhinitis (Ren et al. 2023). P2RX7 variants interact with distal and more etiological stressors in influencing the severity of anxiety symptoms (Kristof et al. 2023). P2X7 receptor inhibition ameliorates ubiquitin-proteasome system dysfunction associated with Alzheimer's disease (Bianchi et al. 2023). P2X7R radioligands are reliable tools for the diagnosis of neuroinflammation in clinical studies, and detection and measurement of free P2X7 receptor (or the P2X7 subunit) in human blood suggested its potential use as a circulating marker of inflammation (Di Virgilio et al. 2023). There are  three frequent coding polymorphisms in the gene for the human P2X7 ion channel, and their functions are known (Schäfer et al. 2022). A P2X7 receptor blockade reduces pyroptotic inflammation and promotes phagocytosis in Vibrio vulnificus infection (Wann et al. 2023). Niemann-Pick disease type C is a rare autosomal recessive of lysosomal storage disorder characterized by impaired intracellular lipid transport and has a tendency to accumulate the fatty acids and glycosphingolipids in a variety of neurovisceral tissues, and the mutational impact in causing Niemann-Pick disease type C has been studied (Kannan et al. 2023). Receptor agonists and antagonists and other modulators of purinergic signalling have potential as novel therapeutics for a broad range of diseases and conditions. An up-to-date description of selected efforts to discover and develop new small molecular purinergic drugs has appeared (Jacobson and Salvemini 2023). Astrocytes induce ischemic tolerance via P2X7 receptor-mediated lactate release (Hirayama et al. 2024). P2X7 receptors in dendritic cells and macrophages have implications in antigen presentation and T lymphocyte activation (Acuña-Castillo et al. 2024).  Huang et al. demonstrate that the complex of sodium/potassium-transporting ATPase subunit alpha (NKAα1) and purinergic P2X7 receptor (P2X7R) maintains the resting state of microglial membranes. Stress increases free P2X7R that then binds to ATP to activate microglia, which may promote anxious behaviors (Fang and Lai 2024).

Animals

P2X7 of Homo sapiens (Q99572)

 
1.A.7.1.4

The P2X4 receptor (P2X4R) of the zebrafish of 389 aas and 2 TMSs. The 3-d structure is known in its closed, resting state (Kawate et al., 2009).  A hift of L340 packing between different sites may alter the side-chain orientation that frees or occludes the pore. L340, A344 and A347 may also gate the pore by a expansion-contraction mechanism (Li 2015). Ivermectin binds to the transmembrane domain while Zn2+ binds to the extracellular domain, but they exhbit additive cooperativity (Latapiat et al. 2017).

Animals

P2X(4) purinoceptor (ATP) gated ionotropic receptor, subunit 4 of Danio rerio (Q98TZ0)

 
1.A.7.1.5

The purinergic receptor, P2X4, is sensitive to the macrocyclic lactone, ivermectin, which allosterically modulates both ion conduction and channel gating (Samways et al., 2012). The secondary structure and gating rearrangements of TMSs in rat P2X4 receptor channels have been proposed (Silberberg et al. 2005). Bile acids inhibit the human P2X4 (Ilyaskin et al. 2019). The gating mechanism has been discussed (Du et al., 2012) and considered to be determined by the conformation of the transmembrane domain (Minato et al. 2016; Pierdominici-Sottile et al. 2016). The crystal structure of the ATP-gated P2X4 ion channel in the closed state has been reported (Kawate et al., 2009). Unobstructed lateral portals are preferentially used as access routes to the pores of P2X receptors (Samways et al., 2011).  Activation is ATP-dependent and rapid, but desensitization occurs within seconds and is ATP-independent (Stojilkovic et al. 2010). Ectodomain cysteines play roles in agonist binding and channel gating (Rokic et al. 2010).  Evermectin has distinct effects on opening and dilation of the channel pore, the first accounting for increased peak current amplitude, and the latter correlating with changes in the kinetics of receptor deactivation (Zemkova et al. 2014). Conserved amino acids within the regions linking the ectodomain with the pore-forming transmembrane domain may contribute to signal transduction and channel gating (Gao et al. 2015; Jelínkova et al. 2008). Binding of ATP produces distortions in the chains that eliminate restrictions on the interchain displacements, leading to the opening of the pore (Pierdominici-Sottile et al. 2016). The purinergic receptors, P2RX4 and P2RX7, affect susceptibility to multiple sclerosis (MS) (Sadovnick et al. 2017). P2X4 modulators are used for the treatment of alcohol use disorders (Reyes-Espinosa et al. 2020). Lithocholic acid inhibits P2X2 and potentiates P2X4 receptor channel gating (Sivcev et al. 2020). Therapeutic targeting of the P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma modelshas been achieved (Rupert et al. 2023). A role for KATP channels in cytotoxicity of cells that are primed for a rapid immune response has been reported (Feske et al. 2024).

Animals

P2X4 of Homo sapiens (Q99571)

 
1.A.7.1.6

ATP-gated P2X3 receptor. Tyr-37 stabilizes desensitized states and restricts calcium permeability (Jindrichova et al., 2011).  Exhibits "high affinity desensitization" but slow reactivation from the desensitized state (Giniatullin and Nistri 2013). An endogenous regulator of P2X3 in bladder is the Pirt protein (TC#8.A.64.1.1) Gao et al. 2015).  X-ray crystal structures of the human P2X3 receptor in apo/resting, agonist-bound/open-pore, agonist-bound/closed-pore/desensitized and antagonist-bound/closed states have been determined (Mansoor et al. 2016). The open state structure harbours an intracellular motif termed the 'cytoplasmic cap', which stabilizes the open state of the ion channel pore and creates lateral, phospholipid-lined cytoplasmic fenestrations for water and ion egress. P2X3 receptor antagonism attenuates the progression of heart failure (Lataro et al. 2023).  Standardized Centella asiatica extract ECa 233 alleviates pain hypersensitivity by modulating P2X3 (Wanasuntronwong et al. 2024). When P2X3 is in its apo state, its ICD architecture is fairly ordered rather than an unstructured outward folding, enabling allosteric modulation of the signaling of P2X3 receptors (Lin et al. 2024).

Animals

P2X3 receptor of Homo sapiens (P56373)

 
1.A.7.1.7

P2X purinoceptor

Fish

P2X purinoceptor of Tetaodon nigroviridis

 
1.A.7.1.8

The p2X purinoreceptor 4a of 389 aas and 2 TMSs, P2X4a of 388 aas and 2 TMSs. A splice variant of 361 aas also exists and may form heterotrimers with P2RX4a (Townsend-Nicholson et al. 1999). Plays a role in alcoholism (Franklin et al. 2014). P2RX4 deficiency alleviates allergen-induced airway inflamation (Zech et al. 2016).

P2X4a of Mus musculus (Mouse)

 
1.A.7.1.9

Purinorepector, P2X7 (P2RX7) of 595 aas and 2 TMSs.  The crystal structure in complex with a series of allosteric antagonists were published, giving insight into the mechanism of channel antagonism (Pasqualetto et al. 2018). A P2RX7 single nucleotide polymorphism haplotype promotes exon 7 and 8 skipping and disrupts receptor function (Skarratt et al. 2020).

P2X7 of Ailuropoda melanoleuca (Giant panda)

 
Examples:

TC#NameOrganismal TypeExample
1.A.7.2.1

The osmoregulatory intracellular P2X receptor, P2XA gated by ATP (present in the osmoreulatory organelle, the contractile vacuole) (Fountain et al., 2007). One of five P2X receptors in D. discoideum is localized to the contractile vacuole with the ligand binding domain facing the lumen. Plays a role in Ca2+ signaling, but also is Cl- permeable. May function in osmoregulation (Ludlow et al., 2009).  Four of the five receptors operate as ATP-gated channels (P2XA, P2XB, P2XD, and P2XE). For the P2XA receptor, ATP was the only effective agonist, but extracellular sodium, compared with potassium, strongly inhibited ATP responses in P2XB, P2XD, and P2XE receptors. Increasing the proton concentration (pH 6.2) accelerated desensitization at P2XA receptors and decreased currents at P2XD receptors, but increased the currents at P2XB and P2XE receptors. Dictyostelium lacking P2XA receptors showed an impaired regulatory volume decrease in hypotonic solution. This phenotype was rescued by overexpression of P2XA and P2XD receptors, partially rescued by P2XB and P2XE receptors, and not rescued by P2XC receptor which appeared to be inactive (Baines et al. 2013).

Slime mold

P2XA of Dictyostelium discoideum (Q55A88)

 
1.A.7.2.10

Partial seqence of a putative P2XR of 273 aas and 1 TMS at residue 150 in the protein.

Putative P2XR of an archaeon (phyllosphere metagenome)

 
1.A.7.2.11

Uncharacterized protein of 507 aas and 2 TMSs, N- and C-terminal.

UP of Cafeteria roenbergensis

 
1.A.7.2.12

Uncharacterized protein of 521 aas and 5 TMSs in a 3 (N-terminal) + 1 (residues 145 - 165) + 1 (residues 430 - 455).

UP of Capsaspora owczarzaki

 
1.A.7.2.13

Uncharacterized protein of 477 aas and 2 TMSs, near the N- and C-termini.

UP of Polarella glacialis

 
1.A.7.2.14

p2x receptor of 448 aas and 2 TMSs, near the N- and C-termini.

 

p2x receptor of Chrysochromulina tobinii

 
1.A.7.2.15

Uncharacterized protein of 653 aas and 1 centrally located TMS.  This protein may be a fragment, but shows appreciable sequence identity with members of the P2X family.

UP of an archaeon (phyllosphere metagenome)

 
1.A.7.2.2

Uncharacterized P2X recpetor of 399 aas and 2 TMSs/

UP of Guillardia theta

 
1.A.7.2.3

Uncharacterized P2X receptor of 524 aas and 2 TMSs.

UP of Emiliania huxleyi (Pontosphaera huxleyi)

 
1.A.7.2.4

Uncharacterized protein of 488 aas and 2 TMSs.

UP of Vitrella brassicaformis

 
1.A.7.2.5

P2X receptor E isoform X1 of 397 aas and 2 TMSs, N- and C-terminal.

P2XR of Nematostella vectensis

 
1.A.7.2.6

P2X receptor of 373 aas and 2 TMSs, N- and C-terminal.

P2XR of Planoprotostelium fungivorum

 
1.A.7.2.7

Uncharacterized P2X receptor of 458 aas and 2 TMSs, N- and C-terminal.

UP of Catenaria anguillulae

 
1.A.7.2.8

Uncharacterized protein of 396 aas and 2 TMSs, N- and C-terminal.

UP of Rhizophagus diaphanus

 
1.A.7.2.9

P2X receptor E of 1271 aas and 4 TMSs roughly equidistant from each other, at positions 311, 627, 918, and at the C-terminus. The region showing sequence similarity with other members of the P2XR family is residues 300 to 640, including TMSs 1 and 2 of the 3 distinct TMSs.

P2XR E of Symbiodinium microadriaticum

 
Examples:

TC#NameOrganismal TypeExample